Bio-Techne TECH Royalty — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bio-Techne in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Bio-Techne’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bio-Techne's royalty — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bio-Techne's royalty — revenue?
- Bio-Techne (TECH) reported royalty — revenue of $4.97M in Q1 2026.
- How has Bio-Techne's royalty — revenue changed year-over-year?
- Bio-Techne's royalty — revenue decreased by 1.4% year-over-year, from $5.04M to $4.97M.
- What is the long-term trend for Bio-Techne's royalty — revenue?
- Over 4 years (2021 to 2025), Bio-Techne's royalty — revenue has grown at a 5.9% compound annual growth rate (CAGR), from $18.85M to $23.69M.
- What does royalty — revenue mean?
- Revenue earned from licensing intellectual property and proprietary technologies to third parties.
- How do you interpret royalty — revenue?
- An increase indicates successful commercialization of proprietary technology and growing adoption by external partners, while a decrease may signal expiring patents or reduced market demand for licensed assets.
- How does royalty — revenue compare across companies?
- Comparable to royalty income or licensing revenue reported by other life sciences and biotechnology firms that monetize intellectual property portfolios.